A protectin DX (PDX) analog with in vitro activity against influenza A(H1N1) viruses
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Nicolas Fortin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Center in Infectious Diseases, CHU de Québec-Université Laval, Quebec City, Canada. Hauptthemen laut MEDLINE: Influenza A Virus, H1N1 Subtype, Influenza, Human, Influenza A virus, Triazines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Antiviral therapy based on neuraminidase (oseltamivir) or polymerase (baloxavir marboxil) inhibitors plays an important role in the management of influenza infections. However, the emergence of drug resistance and the uncontrolled inflammatory response are major limitations in the treatment of severe influenza disease. Protectins D1 (PD1) and DX (PDX), part of a family of pro‐resolving mediators, have previously demonstrated anti‐influenza activity as well as anti‐inflammatory properties in various clinical contexts. Herein, we synthetized a series of simplified PDX analogs and assessed their in vitro antiviral activity against influenza A(H1N1) viruses, including oseltamivir‐ and baloxavir‐resistant variants. In ST6GalI‐MDCK cells, the PDX analog AN‐137B reduced viral replication in a dose‐dependent manner with IC 50 values of 23.8 for A/Puerto Rico/8/1934 (H1N1) and between 32.6 and 36.7 µM for susceptible and resistant A(H1N1)pdm09 viruses. In MTS‐based cell viability experiments, AN‐137B showed a 50% cellular cytotoxicity (CC 50 ) of 638.7 µM with a resulting selectivity index of 26.8. Of greater importance, the combination of AN‐137B with oseltamivir or baloxavir resulted in synergistic and additive in vitro effects, respectively. Treatment of lipopolysaccharide (LPS)‐stimulated macrophages with AN‐137B resulted in a decrease of iNOS activity as shown by the reduction of nitrite production, suggesting an anti‐inflammatory effect. In conclusion, our results indicate that the protectin analog AN‐137B constitutes an interesting therapeutic modality against influenza A virus, warranting further evaluation in animal models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center in Infectious Diseases, CHU de Québec-Université Laval, Quebec City, Canada.
- Medicinal Chemistry Platform, CHU de Québec-Université Laval, Quebec City, Canada.
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Fortin, N., Hénaut, M., Goyette, N., Maltais, R., Sancéau, J. Y., Marette, A., Poirier, D., Abed, Y., & Boivin, G. (2024). A protectin DX (PDX) analog with in vitro activity against influenza A(H1N1) viruses. Journal of Medical Virology. https://doi.org/10.1002/jmv.29484
Vancouver
Fortin N, Hénaut M, Goyette N, Maltais R, Sancéau JY, Marette A, et al. A protectin DX (PDX) analog with in vitro activity against influenza A(H1N1) viruses. Journal of Medical Virology. 2024. doi:10.1002/jmv.29484
BibTeX
@article{Fortin2024,
author = {Fortin, Nicolas and Hénaut, Mathilde and Goyette, Nathalie and Maltais, René and Sancéau, Jean-Yves and Marette, André and Poirier, Donald and Abed, Yacine and Boivin, Guy},
title = {A protectin DX (PDX) analog with in vitro activity against influenza A(H1N1) viruses},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29484}
}
EUVIMED